Introduction {#S1}
============

Gene expression profiling is an important tool to understand pharmacological effects of drugs in complex biological systems ([@B23]; [@B9]; [@B27]; [@B22]; [@B43]; [@B31]). It is now well known that overexpression of certain genes (e.g., wild-type (wt) p53 gene) controls DNA damage, its repair, and cell survival ([@B28]; [@B23]; [@B9]; [@B22]). Topotecan (TPT, [Figure 1](#F1){ref-type="fig"}), a water-soluble analog of camptothecin (CPT), is an important anticancer agent for the treatment of various human malignancies in the clinic ([@B47]). It is currently used in refractory ovarian cancer as well as for the management of small cell lung carcinoma ([@B25]; [@B16]; [@B17]). While TPT is not currently utilized for the treatment of breast cancer, it has shown significant activities against breast tumors and is currently used for the treatment of metastatic breast cancer ([@B36]; [@B58]). The major mechanism of action of TPT is believed to results from the formation of highly cytotoxic double-stranded DNA damage produced by the ternary complex formed by DNA-topotecan, and topoisomerase I ([@B39]; [@B48]). However, other mechanisms of action of TPT have also been reported e.g., induction of oxidative stress ([@B1]; [@B56]) and inhibition of hypoxia-inducible factor ([@B44]; [@B42]). Various investigators ([@B1]; [@B56]) have reported that TPT induced formation of reactive oxygen species (ROS) in human breast MCF-7 tumor cells. Furthermore, significant decrease in glutathione levels as well as enhancement of lipid peroxidation was observed following TPT treatment. These authors have also found significant increases in levels of antioxidant enzymes, superoxide dismutase, glutathione peroxidase and catalase, following TPT treatment, indicating oxidative stress was induced in MCF-7 tumor cells by TPT. We have recently shown that in the presence of H~2~O~2~ and peroxidases, TPT generates a TPT radical (TPT^•^), which rapidly reacts with glutathione and cysteine, forming the corresponding GS^•^ and Cys^•^ radicals and regenerating TPT ([@B51]). It has been shown by several investigators that ROS, produced by arsenic trioxide, and H~2~O~2~ cytotoxicity is partly mediated by the formation of DNA-topo I complexes ([@B10]; [@B52]). These observations, taken together, suggest that TPT-dependent ROS formation could also contribute to topo I-induced DNA damage and cytotoxicity.

![Structure of Topotecan. Phenolic OH, shown in red, is oxidized by peroxidases to generate the corresponding phenoxy radical.](fgene-11-00775-g001){#F1}

Since a direct effect of free radicals generated by TPT in its cytotoxicity in MCF-7 tumor cells was not addressed in our previous study although we found that that ascorbic acid, a cellular generator of hydrogen peroxide, was extremely synergistic with TPT in inducing cell death ([@B51]). To further define the involvement of free radical-mediated pathways in the mechanism (s) in TPT-induced tumor cell death, we have now utilized global gene expression induced by TPT following 1 and 24 h treatment in MCF-7 breast tumor cells. We choose these time points as our preliminary experiments indicated that MCF-7 cells were not affected (showed no sign of cell death) at 1 h and but showed about 35--40% cell death at 24 h of TPT exposure. We believe that examination of differential gene expression at these time points would be indicative of genes and, therefore, pathways and mechanisms responsible for TPT-induced cell death in MCF-7 cells. We found that TPT significantly modulates ERα/ESR1 and BCL2 genes, in addition to several p53-dependent DNA damage repair genes at 24 h of TPT exposure. Furthermore, various ROS sensor genes were also differentially regulated at 24 h by TPT. We also utilized another human breast ZR-75-1 tumor cell line to confirm differential regulations of these genes using RT-PCR. Thus, up-regulation of p53-dependent pathways and down-regulation of ERα/ESR1, BCL2 and ROS sensor genes are extremely important in the mechanism of cytotoxicity of TPT.

Materials and Methods {#S2}
=====================

Materials {#S2.SS1}
---------

Topotecan hydrochloride was purchased from Cayman Chemicals (Ann Arbor, MI, United States). TPT was dissolved in doubly distilled water, and solutions were stored at −80°C.

Cell Culture and Drug Treatment {#S2.SS2}
-------------------------------

Human breast MCF-7 (ATCC, Rockville, MD, United States) tumor cells were grown in Phenol Red-free RPMI 1640 media and supplemented with 10% fetal bovine serum and antibiotics. Human breast ZR-75-1 tumor cells (ATCC, Rockville, MD, United States) were grown in Gibco's DMEM medium containing glucose and glutamine and supplemented with 10% FBS and antibiotics. Both tumor cells were routinely used for 20--25 passages, after which the cells were discarded, and a new cell culture was started from the frozen stock. Three independent experiments of exponentially growing MCF-7 cells (70--75% confluency) were left untreated or treated with TPT (1 μM) for 1 and 24 h. ZR-75-1 cells were treated with TPT (1 μM) for 24 h. Cells were washed twice with PBS (pH 7.4) and total RNA was extracted with TRIzol (Ambion, Life Technologies, Grand Island, NY, United States) and RNeasy mini kit columns (Qiagen, Valencia, CA, United States).

Global Gene Expression and Data Acquisition {#S2.SS3}
-------------------------------------------

Gene expression analysis was conducted using Agilent Whole Human Genome 4×44K multiplex format oligo arrays (014850) (Agilent Technologies, Santa Clara, CA, United States) following the Agilent 1-color microarray-based gene expression analysis protocol. Starting with 500 ng of total RNA, Cy3 labeled cRNA was produced per manufacturer's protocol. For each sample, 1.65 μg of Cy3 labeled cRNAs were fragmented and hybridized for 17 h in a rotating hybridization oven. Slides were washed and then scanned with an Agilent Scanner. Data was obtained using the Agilent Feature Extraction software (v12), using the 1-color defaults for all parameters. The Agilent Feature Extraction Software performed error modeling, adjusting for additive and multiplicative noise. The resulting data were processed using OmicSoft Array Studio (Version 10.1) software.

Preprocessing of the Data {#S2.SS4}
-------------------------

Pixel intensity values of probes that map to the same gene were averaged. The data was log2 transformed and quantile normalized. To remove noisy genes at the low end of the intensity distribution, genes above the 40th percentile in 18 of 24 samples were retained. Thus, 32, 379 genes were filtered down to 18, 248 genes.

Statistical Data Analysis {#S2.SS5}
-------------------------

The following two-way analysis of variance (ANOVA) was used to model the log2 quantile normalized data from the 18,248 genes passing the low intensity filter:
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where μ is grand mean of the experiment, *Y*~*ijk*~ represents the *k*th gene expression observation on the *i*th compound (C) and *j*th time (T) and *ε~*ijk*~* the random error assumed to be normally and independently distributed with mean 0 and standard deviation *δ* for all measurements. Fisher's least significant difference *t*-test was performed for each gene to compare the mean of the Topo 24 h samples and WT to the mean of the control 24 h samples. Differentially expressed genes (DEGs) were detected at a [@B4] false discovery rate (FDR)\<0.05 and absolute fold change \>2.0. Using the Database for Annotation, Visualization, and Integrated Discovery (DAVID) v6.8 ([@B18], [@B19]) the 2,941 DEGs were enriched for KEGG pathways and Gene Ontology biological processes at an FDR ≤0.05 with minimum category size ≥5.

Pattern-Driven Analysis of Gene Expression {#S2.SS6}
------------------------------------------

To identify patterns in 18,248 filtered genes, ratio values for each gene were generated by subtracting the average log2 quantile normalized pixel intensity of the time-matched controls from the log2 quantile normalized pixel intensity of the time-matched samples. The ratio values were then analyzed to extract patterns and identify co-expressed genes using the EPIG software ([@B7]) with the EPIG parameters Pearson correlation ≥0.7, signal/noise ≤2.5, minimum pattern size ≥6, magnitude of fold change \>0.5 and *p*-value \< 0.0001.

Real-Time RT-PCR {#S2.SS7}
----------------

The expression levels of selected transcripts were confirmed by real-time polymerase chain reaction (RT-PCR) using absolute SYBR green ROX Mix (Thermo Fisher Scientific, Rochester, NY, United States). Data were analyzed using ΔΔCt method of relative quantification in which cycle times were normalized to β-actin from the same sample. Primers for the selected genes were designed using Primer Express 1.0 software and in some cases were synthesized (Integrated DNA Technologies, San Diego, CA, United States) from published literature. All real-time fluorescence detection was carried out on an iCycler (Bio-Rad, Hercules, CA, United States). Statistical analysis represents the mean ± SEM from three independent experiments and were performed using unpaired Student's *t*-test and considered significant when *p* ≤ 0.05.

Results {#S3}
=======

Enrichment analysis of the 2,197 genes (2,604 transcripts, [Supplementary Table 1](#TS1){ref-type="supplementary-material"}) showing significant differences between 24 h-treated MCF-7 tumor cells and vehicle-treated controls are presented in [Tables 1](#T1){ref-type="table"}--[3](#T3){ref-type="table"}. Using KEGG pathways, the gene ontology (GO) biological process and Ingenuity Pathway analysis (IPA), p53 signaling pathway, DNA replication, and positive regulator of apoptotic process were identified to be significantly enriched. We also found that DEGs involved in DNA repair pathways were also over-expressed following TPT treatment.

###### 

Enrichment of biological pathways by the TPT at 24 h differentially expressed genes.

  KEGG pathway            KEGG Term   Gene Count   Pop Hits   \%     Fold Enrichment   FDR (%)
  ----------------------- ----------- ------------ ---------- ------ ----------------- ---------
  p53 signaling pathway   hsa04115    29           67         1.37   3.79              2.4E-07
  Cell cycle              hsa04110    39           124        1.84   2.76              6.3E-06
  DNA replication         hsa03030    19           36         0.90   4.62              1.4E-05

Based on KEGG enrichment of the 2,197 DEGs (2,604 transcripts) using the David Database v6.8. The population (pop) total = 6,879 and the list total = 785. FDR: false discovery rate.

###### 

Enrichment of biological processes by the TPT at 24 h differentially expressed genes.

  BP                                                                                              BP Term      Gene Count   Pop Hits   \%     Fold Enrichment   FDR (%)
  ----------------------------------------------------------------------------------------------- ------------ ------------ ---------- ------ ----------------- ----------
  DNA replication                                                                                 GO:0006260   53           155        2.50   3.18              3.38E-11
  G1/S transition of mitotic cell cycle                                                           GO:0000082   35           102        1.65   3.19              1.37E-06
  Cellular response to DNA damage stimulus                                                        GO:0006974   51           208        2.41   2.28              5.70E-05
  Cell division                                                                                   GO:0051301   71           350        3.35   1.89              3.50E-04
  DNA replication initiation                                                                      GO:0006270   16           32         0.75   4.65              4.99E-04
  DNA repair                                                                                      GO:0006281   53           235        2.50   2.10              5.31E-04
  Positive regulation of GTPase activity                                                          GO:0043547   100          565        4.72   1.65              0.001
  Telomere maintenance via recombination                                                          GO:0000722   15           32         0.71   4.36              0.004
  Positive regulation of apoptotic process                                                        GO:0043065   60           300        2.83   1.86              0.006
  DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest   GO:0006977   21           62         0.99   3.15              0.008
  CENP-A containing nucleosome assembly                                                           GO:0034080   17           43         0.80   3.68              0.009
  G2/M transition of mitotic cell cycle                                                           GO:0000086   34           137        1.60   2.31              0.012
  Sister chromatid cohesion                                                                       GO:0007062   28           103        1.32   2.53              0.015
  Signal transduction                                                                             GO:0007165   171          1161       8.07   1.37              0.023
  Mitotic nuclear division                                                                        GO:0007067   50           248        2.36   1.88              0.033

Based on GO biological process (BP) enrichment of the 2,197 DEGs (2,604 transcripts) using the David Database v6.8. The population (pop) total = 16,792 and the list total = 1,804. FDR: false discovery rate.

###### 

Canonical pathways impacted by the TPT at 24 h differentially expressed genes.

  Ingenuity canonical pathways                        Ratio   z-score   −log(*p*-value)
  --------------------------------------------------- ------- --------- -----------------
  p53 signaling                                       0.28    2.71      7.89
  Molecular mechanisms of cancer                      0.18    NaN       7.15
  Estrogen-mediated S-phase Entry                     0.46    −2.31     5.98
  Cell cycle: G2/M DNA damage checkpoint regulation   0.34    1         5.91
  Role of BRCA1 in DNA damage response                0.28    −0.54     5.67
  Mitotic roles of polo-like kinase                   0.29    0.26      5.3
  Cell cycle control of chromosomal replication       0.30    NaN       5.15
  Breast cancer regulation by stathmin1               0.19    NaN       4.68
  NER pathway                                         0.22    −0.23     4.28
  Axonal guidance signaling                           0.15    NaN       4.24
  Cell cycle: G1/S checkpoint regulation              0.25    1.07      4.04

NaN, No activity pattern detected.

[Table 4](#T4){ref-type="table"} shows a list of some of the DNA repair genes significantly affected following TPT treatment (24 h). Of interest are significant decreases (4.5-fold) related to DNA damage repair genes, e.g., O^6^-methylguanine-DNA methyl transferase (*MGMT*) gene and 8-oxoguanine DNA glycosylase (*OGG1*) gene following TPT treatment. *MGMT* is responsible for the removal (and repair) of alkyl groups from DNA and protects cells from cytotoxic effects of alkylating anticancer drugs. *OGG1* is involved in the repair of 8-oxoguanine, formed from reactions of hydroxyl radical with DNA. DNA repair gene, p53-dependent *RAD51* was also significantly decreased (4.0-fold) following TPT treatment. *RAD51* is known to be involved in homologous repair of DNA double strand breaks following DNA damage in a p53-dependent mechanism ([@B2]; [@B14]; [@B35]). The growth arrest and DNA damage 45 alpha gene (*GADD45α*) was significantly (16.8-fold) induced. GADD45α is a stress and DNA damage response protein and is increased during growth arrest following treatment with DNA damaging drugs.

###### 

DNA repair genes differentially regulated by TPT 24 h treatment in MCF-7 tumor cells.

  GenBank Acc. \#        Probe ID                     Gene Symbol   Description                                                                             Log2 Fold-Change
  ---------------------- ---------------------------- ------------- --------------------------------------------------------------------------------------- ------------------
  NM_016819, NM_002542   A_24_P414183, A_23_P344392   OGG1          8-oxoguanine DNA glycosylase                                                            −2.1
  NM_006763              A_23_P62901                  BTG2          BTG family, member 2                                                                    5.0
  NM_000057              A_23_P88630                  BLM           Bloom syndrome, RecQ helicase-like                                                      −2.6
  NM_000123              A_23_P117225                 ERCC5         excision repair cross-complementing rodent repair deficiency, complementation group 5   2.3
  NM_005244              A_23_P500421                 EYA2          eyes absent homolog 2 (Drosophila)                                                      −5.8
  NM_000135              A_23_P206441                 FANCA         Fanconi anemia, complementation group A                                                 −2.7
  NM_000136              A_23_P32021                  FANCC         Fanconi anemia, complementation group C                                                 −6.4
  NM_001018115           A_32_P24165                  FANCD2        Fanconi anemia, complementation group D2                                                −3.6
  NM_018193              A_32_P95729                  FANCI         Fanconi anemia, complementation group I                                                 −3.1
  NM_002431              A_23_P32615                  MNAT1         menage a trois homolog 1, cyclin H assembly factor (Xenopus laevis)                     −2.3
  NM_145080              A_23_P95823                  NSMCE1        non-SMC element 1 homolog (S. cerevisiae)                                               −2.1
  NM_002412              A_23_P104323                 MGMT          O-6-methylguanine-DNA methyltransferase                                                 −4.5
  NM_148894              A_24_P264928                 BOD1L         biorientation of chromosomes in cell division 1-like                                    3.8
  NM_001274              A_23_P116123                 CHEK1         checkpoint kinase 1                                                                     −2.3
  NM_005483              A_24_P53519                  CHAF1A        chromatin assembly factor 1, subunit A (p150)                                           −2.9
  NM_005441              A_23_P57306                  CHAF1B        chromatin assembly factor 1, subunit B (p60)                                            −2.2
  NM_000107              A_23_P52610                  DDB2          damage-specific DNA binding protein 2, 48kDa                                            2.0
  NM_003686              A_23_P23303                  EXO1          exonuclease 1                                                                           −3.1
  NM_001136198           A_23_P142325                 FZR1          fizzy/cell division cycle 20 related 1 (Drosophila)                                     2.3
  NM_004111              A_24_P84898                  FEN1          flap structure-specific endonuclease 1                                                  −2.2
  NM_202002              A_23_P151150                 FOXM1         forkhead box M1                                                                         −5.2
  NM_001924              A_23_P23221                  GADD4A        growth arrest and DNA-damage-inducible, alpha                                           16.8
  NM_002439              A_24_P203479                 MSH3          mutS homolog 3 (E. coli)                                                                −2.1
  NM_001031716           A_24_P229531                 OBFC2A        oligonucleotide/oligosaccharide-binding fold containing 2A                              2.5
  NM_198949              A_23_P134295                 NUDT1         nudix (nucleoside diphosphate linked moiety X)-type motif 1                             −2.1

BCL2, the anti-apoptotic protein, was significantly decreased (8.2-fold) following TPT treatment in the breast MCF-7 tumor cells, suggesting an apoptosis-based cell death. Furthermore, a significant decrease in the ERα receptor gene was also detected following TPT treatment. Interestingly, IPA enrichment of DEGs at 24 h ([Table 4](#T4){ref-type="table"}) shows a central role for ERα receptor and its interactions with various genes involved in TPT-induced cell death ([Figure 2](#F2){ref-type="fig"}). This conclusion is also supported by a previous study ([@B41]) involving treatment of MCF-7 cells with a topoisomerase inhibitor (XR5944), like topotecan, where authors found significant inhibition of ESR1 activity. In our Ingenuity molecular interaction network ([Figure 2](#F2){ref-type="fig"}), many of the DEGs from topotecan exposure at 24 h interact with ESR1 as a central hub. ESR1 is down-regulated as are the majority of the genes in the network.

![IPA molecular interaction network. The 2,197 DEGs (2,604 transcripts) from the comparison of Topotecan at 24 h vs. control at 24 h were used to generate the top scoring (--log~10~ *p*-value = 38) molecular interaction network containing 34 focus molecules. The intensity of the colors represents the fold change of expression; red is up-regulated, and green is down-regulated. The shapes represent molecular entities; diamond: enzyme, oval: transcription regulator, triangle: kinase, rectangle: ligand-dependent nuclear receptor, double circle: complex group, circle: other. Solid lines denote a direct interaction. An arrow symbolizes activation and a line with no arrow signifies a protein-protein interaction.](fgene-11-00775-g002){#F2}

Differential analysis of the 1 h treated samples yielded no significant changes in genes. However, 1,132 gene transcripts were identified as co-expressed in nine patterns across the 1 and 24 h treatments ([Figure 3](#F3){ref-type="fig"} and [Supplementary Table 2](#TS2){ref-type="supplementary-material"}). These co-expressed genes by principal component analysis (PCA) capture more than 96% of the variation in the data, the co-expressed gene group the biological replicates very well and separate the vehicle treated controls (1 and 24 h) from the TPT-treated samples ([Figure 4](#F4){ref-type="fig"}). Furthermore, the 1st principal component (PC \#1) separates 24 h TPT-treated samples from the controls and the 1 h TPT-treated samples. Most co-expressed genes are in pattern \#3 (426 transcripts) and pattern \#9 (552 transcripts). As shown in [Figures 3](#F3){ref-type="fig"}, [5](#F5){ref-type="fig"}, pattern \#3 genes are up-regulated at the 24 h TPT treatment and the pattern \#9 genes down-regulated at the 24 h TPT treatment. Pattern \#3 genes enrich for the p53 signaling pathway and pattern \# 9 genes enrich for DNA replication and cell cycle pathways.

![Heat map of the expression of the co-expressed genes. The log~2~ ratio values of the 1,132 co-expressed genes categorized to the nine EPIG patterns are represented as a heat map. Red is up-regulated, blue is down-regulated, and gray is no change. The color legend depicts the relative expression change (each sample to the average of the time-matched control). The *x*-axis is the samples and the *y*-axis are the genes grouped into the nine patterns colored according to the pattern \# legend.](fgene-11-00775-g003){#F3}

![PCA of the samples. PCA was performed on the 1,132 EPIG co-expressed genes using log2 ratio values (expression of each topotecan sample or control minus the average of the log2 of the time matched controls). The total amount of variability captured by the 1st two principal components (PCs) is 95.2%. The *x*-axis is PC1 (88.3%) and the *y*-axis is PC2 (6.92%). The samples are color coded as depicted in the legend.](fgene-11-00775-g004){#F4}

![EPIG patterns. Expression patterns of genes co-expressed by **(A)** up-regulation by Topotecan (pattern \#3 represents 426 genes) and **(B)** down-regulation by Topotecan (pattern \#9 represents 552 genes). The *x*-axis is the biological samples that are color coded and represented by symbols as depicted in the legend. The *y*-axis is the log~2~ ratio.](fgene-11-00775-g005){#F5}

As TPT treatment at 1 h did not significantly affected expressions of genes, we used the RT-PCR analysis to confirm expression of these representative (from microarray analysis) genes at 24 h in MCF-7 tumor cells ([Figure 6](#F6){ref-type="fig"}). A significant correlation was found between microarray (C) and RT-PCR data (A) for MCF-7 cells. Our RT-PCR studies in ZR-75-1 cells, a wild-type p53-containg human breast tumor cell line, indicated similar results, confirming results obtained in MCF-7 tumor cells ([Figures 6A,B](#F6){ref-type="fig"}). Our results strongly suggest that these genes are similarly regulated by TPT in both cell lines.

![RT-PCR analysis of representative genes regulated by TPT in MCF-7 **(A)** and ZR-75-1 **(B)** breast tumor cells at 24 h.\*\*\*, \*\*, and \* *p* values \<0.0001, \<0.005, and 0.05, respectively, compared to controls. The data in **(C)** was obtained by microarray analysis for MCF-7 cell line and is expressed as the fold change from controls.](fgene-11-00775-g006){#F6}

The microarray analysis also indicated that various oxy-radical sensor genes were also significantly differentially expressed by TPT treatment of MCF-7 breast cancer cells at 24 h. We used RT-PCR then to confirm differential expressions of oxy-radical sensor genes in MCF-7 breast tumor cells. Again, RT-PCR was utilized to examine the effects of TPT on these various oxy-radical sensor genes in ZR-71-1 tumor cells and data in [Table 5](#T5){ref-type="table"} clearly show that there is a significant correlation with microarray and RT-PCR in both MCF-7 and ZR-75-1 cells. Ferredoxin reductase (FDXR) is reported to be involved in p53-mediated apoptosis via generation of ROS in mitochondria ([@B20]). Glutathione peroxidases (GPx) are selenium containing cellular proteins responsible for detoxifications of hydrogen peroxide and lipid peroxides. Data presented in [Table 5](#T5){ref-type="table"} clearly show a significant correlation with data obtained with microarray analysis and RT-PCR data obtained with both MCF-7 and ZR-75-1 tumor cells.

###### 

Oxy-radical sensor genes differentially up-regulated/down-regulated following TPT exposure (24 h) in MCF-7 and ZR-75-1 breast tumor cells.

  Gene Symbol   FC^a^   FC^b^   FC^c^
  ------------- ------- ------- -------
  FDXR          6.4     3.5     5.0
  MSRA          −5.8    −5.0    −6.0
  GSR           −2.2    −2.1    −2.0
  GPx           2.0     4.0     5.0

a

microarray in MCF-7 cell line;

b

RT-PCR in MCF-7 cell line;

c

RT-PCR in ZR-75-1 cells line.

Discussion {#S4}
==========

The main mechanism of TPT-dependent tumor cell killing is based on its known interactions with topoisomerase I that results in the stabilization of DNA-enzyme-drug complexes and the formation of toxic DNA double-strand breaks ([@B39]; [@B48]). While this remains one of the most accepted mechanism of tumor cell death by TPT, several studies indicate that generation of ROS and oxidative stress may also be important in TPT-induced cell death ([@B1]; [@B56]).

Recently, we used MCF-7 breast cancer cells to show that TPT is readily oxidized to a free radical intermediate (TPT^•^) and we found that ascorbic acid, a cellular generator of hydrogen peroxide, was extremely synergistic with TPT in inducing cell death ([@B51]). One of the main reasons for utilizing MCF-7 tumor cells to identify free radical based pathways for TPT-induced tumor cell death was that we have shown that MCF-7 breast tumor cells are extremely efficient in activating adriamycin to its free radical species and these cells contain significant numbers of free radical-based detoxification enzymes e.g., SOD, catalase and GPx ([@B49], [@B50]). In this study, we used microarray gene expression analysis to identify and delineate the roles of various genes responsible for TPT cytotoxicity in human MCF-7 breast tumor cells. We have identified several genes belonging to the p53 signaling pathway, DNA replication, and positive regulators of apoptotic process that were differentially expressed by TPT treatment. Using microarray differential gene expression analysis, [@B11] have reported that topotecan exposure in rat bone marrow resulted in enrichment of cell cycle and DNA replication pathways similar to our observations in this study. It should be noted that the relationship between chromatin remodeling, cell cycle and DNA repair factors are usually not discussed in relation to DNA damage response mechanisms following topotecan exposure. Our analysis described here clearly shows a possible relationship between chromatin remodeling complexes and mechanisms of topotecan toxicity and repair that needs further investigation.

Microarray analysis indicated that several genes involved in DNA damage repair pathways were differentially expressed. We, therefore, utilized RT RT-PCR analysis to confirm results obtained by the microarray analysis in MCF-7 tumor cells. Furthermore, these findings were confirmed in another human wt53-conaining ZR-75-1 breast tumor cell line by RT-PCR. We found that TPT treatment caused significant decreases in both O^6^-methylguanine-DNA methyl transferase (*MGMT*) and 8-oxoguanine DNA glycosylase (*OGG1*) genes. *MGMT* is responsible for the repair of alkyl groups from O^6^-guanine and protects cells from cytotoxic effects of alkylating anticancer drugs, e.g., BCNU and temozolomide (TMZ) ([@B12]; [@B15]; [@B59]; [@B55]). TMZ is currently used for the treatment of glioblastoma multiforme. TMZ is rapidly converted to an alkylating species and forms O^6^-methylguanine for its cytotoxicity. Therefore, the formation and persistence of O^6^-methylguanine is critical for its toxicity. It has been reported that TMZ is significantly more cytotoxic to cells with low MGMT activity and increases in MGMT expression have been shown to play a key role in the development of resistance to TMZ and other similar O^6^-alkylating drugs ([@B37]; [@B34]). Because of the potential of TMZ for the treatment of glioblastoma and other malignancies e.g., metastatic melanoma, it would be ideal to combine TMZ with other anticancer agents. Since our present study demonstrates that treatment of tumors with TPT significantly decreases the expression of *MGMT*, it would be of interest to combine TMZ with TPT for synergistic tumor cell killing. Preliminary studies indicate that co-treatment of MCF-7 tumor cells with TPT (125 nM) with TMZ (100 μM) for 48 h results in synergistic tumor cells death. Under these conditions we found 35--40% cell death with this combination of TPT and TMZ while very little or no cells death was observed with either agent alone. MCF-7 tumor cells are extremely resistant to TMZ due to high MGMT activities. Further studies are currently under active investigation in our laboratory using various mer+ tumors cells, including human brain tumor cell lines which overexpress *MGMT* ([@B37]; [@B34]).

8-Oxoguanine glycosylase (OGG1) is involved in the repair of 8-oxoguanine in DNA which is formed from the oxidation of DNA with hydroxyl radical (OH), generated from the H~2~O~2~ by metal ion catalysis ([@B13]; [@B57]). Formation of 8-oxoguanine in cells has been implicated in oxidative stress. In the present study, *OGG1* was significantly decreased by TPT treatment, suggesting decreased repair of OH radical-mediated 8-oxoguanine and enhanced tumor cell killing. Increases in OGG1 activity have been reported to result in the development/emergence of resistance to ionizing radiation. It is interesting to note that TPT and ionizing radiation act synergistically in inducing tumor cell death ([@B29]; [@B26]; [@B6]). Various anticancer drugs, including doxorubicin and arsenic-containing drugs generate ROS and form 8-oxyguanine in tumor cells ([@B38]; [@B40]). It would, therefore, be ideal to combine TPT with other free radical generating anticancer drugs for enhanced/synergistic tumor cell killing. It is possible that enhanced MCF-7 tumor cell killing observed with TPT and ascorbic acid observed in our previous study may, in part, have resulted from this decrease in OGG1 by TPT ([@B51]).

The present study indicated a significant upregulation of ferredoxin reductase (*FDXR*) and a significant down-regulation of methionine sulfoxide reductase (*MSR*) genes following TPT treatment in both MCF-7 and ZR-75-1 tumor cells. The role of *FXDR* in free radical biology is well established as it has been reported to be involved in p53-mediated apoptosis via generation of ROS in mitochondria ([@B20]), causing oxidative stress in cells. Normal and tumor cells have various protective mechanisms, including induction of cellular antioxidant enzymes (e.g., SOD, catalase, and various peroxidases) as well as DNA repair enzymes for oxidative DNA damage (e.g., glycosylases). Both free and bound methionine are readily oxidized by ROS. In cellular systems, methionine is oxidized to methionine sulfoxide, altering protein confirmation and/or inactivating proteins ([@B45]). Methionine sulfoxide is reduced by methionine sulfoxide reductase (MSR) to methionine using NADPH/thioredoxin reductase/thioredoxin system ([@B45]). Decreases or inactivation of MSR increases sensitivity to ROS-mediated cell killing and has been suggested to be involved in the killing of neutrophils by HOCL, a powerful oxidant inducing oxidation of methionine ([@B33]; [@B5]; [@B46]). We also found a small but a significant decrease in the glutathione reductase gene (GSR) following TPT exposure in MCF-7 tumor cells. GSR is required for the reduction of oxidized glutathione (GSSG) that is formed from the reaction of GSH with increased ROS in cells. Furthermore, TPT treatment caused increases in glutathione peroxidase (GPx) which are selenium containing enzymes that are involved in the removal of peroxides, including lipid peroxides from cells. Modulation of both *GPx* and *GSR* genes have been implicated in the oxidative stress induced by CCl4 in hepatocytes ([@B21]).

Taken together e.g., modulations of *FXDR*, *MSR*, *GSR*, and *GPx* genes by TPT in MCF-7 (and ZR-75-1) tumor cells strongly indicate formation of ROS and induction of cellular imbalance of homeostasis, resulting in increased oxidative stress by TPT. This would lead to the formation of cytotoxic species and damage to critical cellular macromolecules. This is further supported by our results showing a significant decrease in *OGG1* gene expression, the DNA repair enzyme for 8-oxoguanine, indicating decrease in repair of oxidant-dependent damaged DNA. These results indicate that increased cellular ROS formation and resulting oxidative stress may have implications in the TPT-induced tumor cell death.

Finally, our studies indicate a significant down-regulation of ERα/ESR1 by TPT treatment. It is interesting to note that XR5944, a topoisomerase I poison, has also been reported to down-regulate *ESR1*, similar to our observations. A significant amount of published data would suggest that ERα/ESR1 is involved in apoptosis, cell death and drug resistance ([@B30]; [@B54]; [@B3]; [@B8]; [@B60]). [@B8] have shown that the knock-down of ERα receptor leads to ROS-mediated autophagy and cell death in breast cancer cells. In addition, studies of [@B30] indicate that treatment of MCF-7 breast cancer cells with estrogen decreases the cell's ability to metabolize H~2~O~2~, resulting in increased sensitivity to DNA damage by peroxides. It is also interesting to note that this treatment of MCF-7 cancer cells also resulted in decreased levels of GSH, and increased activities of both GPx and SOD ([@B30]), results which are similar to those reported in this manuscript with TPT treatment of both MCF-7 and ZR-75-1 cancer cells. Taken together, these observations suggest that ERα is directly involved in free radical mediated tumor cell death. It should also be noted that the antiestrogen drug Tamoxifen is highly synergistic with TPT in cells and in the clinic, indicating that ERα receptor signaling is involved in TPT-induced cell death in ERα positive tumor cells ([@B53]; [@B32]; [@B24]). BCL2, the anti-apoptotic protein was significantly decreased following TPT treatment in the MCF-7 tumor cells, suggesting an apoptosis-based cell death. Based on the heat map ([Figure 3](#F3){ref-type="fig"}) of genes up-regulated and down-regulated following TPT treatment, and the Ingenuity Pathway Analysis of the differentially expressed genes (DEGs) at 24 h, a central role for ERα receptor and its interactions with various genes involved in TPT-induced cell death is apparent ([Figure 2](#F2){ref-type="fig"}). Based on these findings, a possible ROS-dependent mechanism of tumor cell death by TPT is proposed and is shown in [Figure 7](#F7){ref-type="fig"}.

![Topotecan-induced modulation of free radical sensing genes, up-regulation of ROS production, and regulation of cell proliferation and death.](fgene-11-00775-g007){#F7}

Conclusion {#S5}
==========

Our study shows that treatment of human breast MCF-7 tumor cells with TPT results in DEGs that regulate p53-dependent pathways as well as genes that regulate apoptosis. Our results also indicate a central role of ERα in TPT cytotoxicity. Furthermore, expressions of DNA damage repair genes, *MGMT* and *OGG*, were found to be significantly decreased following TPT treatment. Our study has further identified several genes, *FDXR, MSR, GSR*, and *GPx*, involved in maintenance of cellular homeostasis due to increased ROS formation, were differentially expressed by TPT, indicating a putative role of ROS and oxidative stress in TPT cytotoxicity.

Data Availability Statement {#S6}
===========================

The datasets generated for this study can be found in the NCBI's Gene Expression Omnibus (GEO) and are accessible through GEO Series accession number [GSE138442](GSE138442) (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138442>).

Author Contributions {#S7}
====================

BS conceived and designed the experiments. BS and ET performed the experiments. BS, ET, and PB analyzed the data. BS, ET, and PB wrote the manuscript. All authors contributed to the article and approved the submitted version.

Disclaimer {#des}
==========

Statements contained herein do not necessarily represent the statements, opinions, or conclusions of NIEHS, NIH, or the US Government.

Conflict of Interest {#conf1}
====================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Funding.** This research was supported by the intramural research program (grant number ZIA E505013922) of the National Institute of Environmental Health Sciences, NIH.

We thank Dr. Kevin Gerrish for carrying out the microarray gene analysis. We also thank Drs. M. Kadiiska and Keith Shockley for critical evaluations of the manuscript.

Supplementary Material {#S9}
======================

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fgene.2020.00775/full#supplementary-material>

###### 

Excel spreadsheet containing the TPT 24 h treatment differentially expressed genes.

###### 

Click here for additional data file.

###### 

Excel spreadsheet containing the TPT 24 h treatment EPIG down-regulation genes categorized to pattern \#9.

###### 

Click here for additional data file.

BCL2

:   B cell lymphoma 2

ER α /ESR1

:   estrogen receptor alpha

FDXR

:   ferredoxin reductase

GPx

:   glutathione peroxidases

GSR

:   glutathione reductase

MGMT

:   O^6^-methylguanine-DNA methyltransferase

MSR

:   methionine sulfoxide reductase

OGG1

:   8-oxoguanine DNA glycosylase1

ROS

:   reactive oxygen species

RT-PCR

:   real-time polymerase chain reaction

TPT

:   topotecan.
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